Business
Immunic, Inc. to Participate in Investor and Scientific Conferences in June
SAN DIEGO, May 30, 2019 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral
About this update from Immunic, Inc.
[{"type":"text","content":"SAN DIEGO, May 30, 2019 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune diseases, today announced management's participation in a number of scientific and investor conferences in June:\nJune 3-6: 2nd Conference on Molecular Mechanisms of Inflammation: Hella Kohlhof, Ph.D., Chief Scientific Officer of Immunic, will present newly available preclinical data on IMU-935, an orally available, inverse agonist of RORγt for the treatment of various inflammatory and autoimmune diseases. The poster presentation will take place at the 2nd Conference on Molecular Mechanisms of Inflammation in Trondheim, Norway on Tuesday, June 4, beginning at 6:00 pm CEST.June 3-6: 2019 BIO International Convention: Immunic's business development team will attend the 2019 BIO International Convention being held in Philadelphia June 3-6.June 24-26: GI Inflammatory Diseases Summit (GIIDS): Dr. Kohlhof will provide a presentation on IMU-838, an orally available, next-generation selective immune modulator in development for the treatment of inflammatory bowel disease (IBD) and multiple sclerosis (MS), including newly available preclinical and clinical data, at the GIIDS in Boston on Monday, June 24 at 3:30 pm ET.June 25: BMO 2019 Prescriptions for Success Healthcare Conference: Daniel Vitt, Ph.D., Chief Executive Officer and President of Immunic, will present a company overview at the BMO 2019 Prescriptions for Success Healthcare Conference in New York on Tuesday, June 25 at 4:00 pm ET. A live audio webcast of the presentation will be available on the \"Events and Presentations\" section of Immunic's website at ir.immunic-therapeutics.com. An archived replay will be available on the company's website for a period of 90 days after the conference.\n \nAbout Immunic, Inc.Immunic, Inc. (Nasdaq: IMUX) is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing three small molecule products: IMU-838 is a selective immune modulator that inhibits the intracellular metabolism of activated ...